Sign In
Buy SAVA
$1.96
+0 (+0%)
At Close: Jun 03, 2026
Cassava Sciences' stock craters after Alzheimer's disease trial fails to meet its goals
08:50am, Monday, 25'th Nov 2024
The biotech says it will discontinue a second trial but will still offer full analyses of the data.
Cassava Sciences, Biohaven And Other Big Stocks Moving Lower In Monday's Pre-Market Session
08:32am, Monday, 25'th Nov 2024
U.S. stock futures were higher this morning, with the Dow futures gaining more than 300 points on Monday.
Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints
07:30am, Monday, 25'th Nov 2024
Simufilam did not show a significant reduction in cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer's disease in the ReThink-ALZ Phase 3 study
Cassava Sciences to Hold Corporate Update on November 25th
08:01pm, Sunday, 24'th Nov 2024
AUSTIN, Texas, Nov. 24, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for Alzheimer's disease, today an
Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer
08:30am, Monday, 18'th Nov 2024
Ms. Nassif brings an extensive track record of successfully developing commercial strategies for multiple FDA-approved drugs
Is Cassava Sciences (SAVA) Outperforming Other Medical Stocks This Year?
10:46am, Friday, 15'th Nov 2024
Here is how Cassava Sciences, Inc. (SAVA) and biote Corp. (BTMD) have performed compared to their sector so far this year.
What Makes Cassava Sciences (SAVA) a New Buy Stock
01:00pm, Tuesday, 12'th Nov 2024
Cassava Sciences (SAVA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Anavex, Cassava Sciences, Panax Ginseng, And The Long-Term Treatment Of Alzheimer's Disease
07:00am, Monday, 11'th Nov 2024
Panax ginseng shows the highest effectiveness in treating Alzheimer's because it inhibits nitro-oxidative stress, scavenges peroxynitrite, and reverses part of its damage, leading to sustained cogniti
Cassava Sciences, Inc. (SAVA) Q3 2024 Earnings Call Transcript
10:21am, Thursday, 07'th Nov 2024
Cassava Sciences, Inc. (NASDAQ:SAVA ) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Rick Barry - President & Chief Executive Officer Eric Schoen - Chief Financial O
Cassava Sciences Reports Q3 2024 Financial and Operating Results
07:55am, Thursday, 07'th Nov 2024
AUSTIN, Texas, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for Alzheimer's disease, today re
Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024
08:30am, Thursday, 31'st Oct 2024
AUSTIN, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, announced today that it will hold a confe
Analysts Believe Cassava Sciences Now Has 300% Upside From Here
08:45am, Wednesday, 30'th Oct 2024
Cassava Sciences Inc. NASDAQ: SAVA is a biotech developing treatments for Alzheimer's disease. The company has a lot of controversy over its lead drug, simufilam, which attempts to go further than all
SAVA Stock Down on Settling Misleading Alzheimer's Study Data Claims
11:06am, Monday, 30'th Sep 2024
Casava stock falls as the company agrees to pay a cumulative fine exceeding $40 million to settle misleading claims charges brought against it by the SEC.
Why Cassava Sciences Stock Dived by Almost 11% Today
06:05pm, Friday, 27'th Sep 2024
The biotech is paying $40 million not to acquire a drug or fund a development program, but to satisfy a regulator. The money is going toward a settlement with the Securities and Exchange Commission.
Cassava's Stock Drops After It Agrees to Pay $40M to Settle SEC Alzheimer's Claims
11:10am, Friday, 27'th Sep 2024
Cassava Sciences (SAVA) shares dropped more than 11% after the company agreed to a $40 million settlement with the Securities and Exchange Commission (SEC) over charges that it manipulated clinical tr
